Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus

Clinical Drug Investigation

Volumn 28, Issue 11, 2008, Pages 697-701

  Kabadi, Udaya M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antihyperglycaemics, therapeutic use; Insulin detemir, therapeutic use; Insulin glargine, therapeutic use; Switch therapy; Type 1 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; IOWA; MALE; MEDICAID; RETROSPECTIVE STUDIES; THERAPEUTIC EQUIVALENCY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 53549098562     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828110-00003     Document Type: Article

References (11)

1. Bott S, Tusek C, Jacobsen LV, et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabet Med 2006; 23 (5): 522-8
2. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24 (6): 635-42
3. Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007; 61 (3): 523-8
4. Gilmer TP, O'Conner PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care 1997; 20 (120): 1847-53
5. Gray A, Raikoi M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes; economic analysis alongside randomized controlled trial (UKPDS 41). BMJ 2000; 320: 1373-8
6. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998; 208: 1490-6
7. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9
8. Skyler JS. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am 1996; 252 (2): 243-54
9. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86
10. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28 (2): 103-17
11. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 353 (9131): 837-53